Bristol to Acquire ZymoGenetics for $885 Million
Kirkland represented Bristol-Myers Squibb Co. in its acquisition of ZymoGenetics Inc in a deal valued at $885 million.
To read the full text of this article, please click here.
Kirkland represented Bristol-Myers Squibb Co. in its acquisition of ZymoGenetics Inc in a deal valued at $885 million.
To read the full text of this article, please click here.
